Global Nanocarrier-Based Vaccine Market Insights, Size, and Forecast By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Oral), By End User (Pharmaceutical Companies, Research Institutions, Hospitals and Clinics), By Nanocarrier Type (Lipid Nanoparticles, Polymer Nanoparticles, Metal Nanoparticles, Dendrimers), By Vaccine Type (Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035
Key Market Insights
Global Nanocarrier-Based Vaccine Market is projected to grow from USD 12.8 Billion in 2025 to USD 45.3 Billion by 2035, reflecting a compound annual growth rate of 14.2% from 2026 through 2035. The market encompasses the development and commercialization of vaccines utilizing nanotechnology platforms to deliver antigenic material, offering enhanced stability, targeted delivery, and improved immunogenicity compared to traditional vaccine formulations. Key market drivers include the increasing global incidence of infectious diseases, the rising demand for more effective and stable vaccine delivery systems, and significant advancements in nanotechnology and immunology research. Furthermore, the ability of nanocarriers to overcome limitations such as antigen degradation, poor bioavailability, and off-target effects associated with conventional vaccines is fueling market expansion. Important trends shaping the market include the rapid adoption of mRNA vaccine technology, which frequently employs nanocarriers for delivery, and a growing focus on developing multi-antigenic vaccines to provide broader protection. The expanding pipeline of nanocarrier-based vaccines for chronic diseases, including cancer and autoimmune disorders, also signifies a pivotal trend.
Global Nanocarrier-Based Vaccine Market Value (USD Billion) Analysis, 2025-2035
2025 - 2035
www.makdatainsights.com
Despite the promising outlook, the market faces certain restraints. High development costs associated with nanotechnology and stringent regulatory approval processes for novel vaccine technologies pose significant hurdles. Potential toxicity concerns and challenges in scaling up manufacturing processes for complex nanocarrier systems also present limiting factors. Nevertheless, substantial market opportunities lie in the development of next-generation vaccines for emerging infectious diseases, particularly those with pandemic potential, where rapid development and deployment are critical. The expanding applications of nanocarriers in gene therapy and personalized medicine also open new avenues for vaccine development. North America currently dominates the global market, driven by robust research and development infrastructure, significant investments in biotechnology, and the presence of numerous key pharmaceutical and biotechnology companies.
Asia Pacific is anticipated to be the fastest-growing region, propelled by increasing healthcare expenditure, a large patient pool, rising awareness regarding preventative healthcare, and a growing number of strategic collaborations and partnerships within the region. Leading market segment is Lipid Nanoparticles, attributed to their proven efficacy, biocompatibility, and versatility in delivering various vaccine types, particularly mRNA vaccines. Key players such as Novartis, Moderna, Biogen, Roche, AbbVie, Johnson & Johnson, GlaxoSmithKline, Pfizer, Genentech, and Bayer are actively engaged in strategic initiatives including research and development investments, product launches, mergers and acquisitions, and collaborations to strengthen their market position and expand their product portfolios in this rapidly evolving landscape. These players are focused on enhancing vaccine stability, improving delivery efficiency, and exploring novel nanocarrier materials to address unmet medical needs globally.
Quick Stats
Market Size (2025):
USD 12.8 BillionProjected Market Size (2035):
USD 45.3 BillionLeading Segment:
Lipid Nanoparticles (68.4% Share)Dominant Region (2025):
North America (38.7% Share)CAGR (2026-2035):
14.2%
Global Nanocarrier-Based Vaccine Market Emerging Trends and Insights
mRNA Delivery Systems Nanoinnovation
mRNA delivery systems represent a significant nanoinnovation in the global nanocarrier based vaccine market, driven by the need for more efficient and stable transport of genetic material. Traditional lipid nanoparticles remain central, but ongoing research focuses on optimizing their composition for enhanced encapsulation efficiency and targeted cellular uptake. Advancements include novel ionizable lipids and pegylation strategies to improve stability and reduce immunogenicity. Beyond lipids, polymer based nanoparticles, viral like particles, and exosomes are emerging as promising alternatives, offering tailored release kinetics and cell specific targeting. These innovations aim to overcome challenges like mRNA degradation, immunogenicity, and manufacturing scalability, ultimately paving the way for safer, more potent, and widely accessible mRNA vaccines across various infectious diseases and cancer immunotherapies.
Targeted Vaccine Nanocarrier Precision
This trend highlights the meticulous engineering of nanocarriers to deliver vaccines with unprecedented accuracy. Researchers are designing these nanoscale platforms to specifically interact with target cells or tissues within the body, ensuring the vaccine payload reaches its intended destination efficiently. This precision minimizes off target effects, enhancing vaccine safety and reducing potential adverse reactions. By tailoring nanocarriers to specific antigens or immune cells, the approach optimizes the immune response, leading to more potent and durable protection against diseases. This targeted delivery also allows for lower vaccine dosages while maintaining high efficacy, a significant advantage for resource constrained environments and for vaccines requiring multiple administrations. The focus is on smart, highly selective delivery mechanisms that revolutionize vaccine performance.
Adjuvant Nanoparticle Enhanced Immunity
Adjuvant nanoparticle enhanced immunity is a significant trend in the global nanocarrier based vaccine market, driven by the need for more potent and long lasting immune responses. These engineered nanoparticles act as sophisticated vaccine adjuvants, precisely delivering antigens and immune stimulators to professional antigen presenting cells. Their nanoscale size and customizable surface properties allow for optimized antigen presentation and targeted activation of specific immune pathways, including both humoral and cell mediated immunity. This precise modulation leads to stronger, broader, and more durable protective immunity with potentially lower antigen doses. The trend is fueled by their ability to overcome limitations of traditional adjuvants, offering improved safety profiles and efficacy against difficult to target pathogens and cancers. This approach promises to revolutionize vaccine design, leading to more effective and versatile vaccines.
What are the Key Drivers Shaping the Global Nanocarrier-Based Vaccine Market
Advancements in Nanocarrier Technology for Enhanced Vaccine Delivery
Advancements in nanocarrier technology for enhanced vaccine delivery represent a pivotal driver in the global nanocarrier based vaccine market. This driver focuses on the continuous innovation in designing and engineering nanoscale delivery systems such as lipid nanoparticles viral like particles polymeric nanoparticles and exosomes. These advancements enable superior vaccine efficacy by protecting antigens from degradation improving antigen presentation to immune cells and facilitating targeted delivery to specific tissues or cells. Researchers are developing smart nanocarriers capable of controlled antigen release or triggered release in response to physiological cues. The ability to encapsulate various vaccine types including mRNA DNA protein subunits and viral vectors with improved stability and bioavailability is crucial. These innovations lead to more potent longer lasting and safer vaccines contributing significantly to market expansion.
Increasing Global Focus on Preventative Healthcare and Disease Control
A growing worldwide emphasis on averting illnesses rather than merely treating them is profoundly influencing the nanocarrier based vaccine market. Nations and international organizations are investing more heavily in public health initiatives aimed at bolstering immunity and controlling the spread of infectious diseases. This shift stems from recognizing the societal and economic burdens posed by widespread outbreaks and chronic conditions. Preventative healthcare strategies are gaining traction globally leading to increased demand for advanced vaccine technologies. Nanocarrier based vaccines offer superior antigen delivery enhanced immune responses and improved stability making them ideal for these ambitious preventative health goals. Their ability to precisely target immune cells and protect vaccine components ensures greater efficacy aligning perfectly with the global drive to proactively safeguard populations against various pathogens. This concerted effort to prevent disease at a global scale fuels the expansion of this innovative vaccine market.
Growing Investment in Vaccine R&D and Strategic Collaborations
Growing investment in vaccine research and development, coupled with strategic collaborations, is a key driver for the nanocarrier based vaccine market. Pharmaceutical companies, academic institutions, and government bodies are increasingly funding the exploration of novel vaccine platforms and delivery systems. Nanocarriers offer significant advantages like enhanced antigen presentation, targeted delivery, improved stability, and controlled release, making them attractive for developing more effective and safer vaccines against infectious diseases and cancer. Partnerships between biotechnology firms and larger pharmaceutical companies facilitate the translation of promising nanocarrier technologies from laboratories to clinical trials and eventual commercialization. These collaborations accelerate innovation, share expertise, and distribute the substantial costs and risks associated with vaccine development, ultimately expanding the nanocarrier based vaccine pipeline and market adoption.
Global Nanocarrier-Based Vaccine Market Restraints
High Development and Manufacturing Costs of Nanocarrier-Based Vaccines
Developing and producing nanocarrier based vaccines entails significant financial hurdles. The advanced materials required for nanocarriers are often expensive to synthesize and purify. Furthermore the specialized equipment necessary for precise formulation and encapsulation of antigens within these nanocarriers adds considerable capital expenditure. Stringent regulatory testing including extensive preclinical and clinical trials to demonstrate safety and efficacy drives up costs substantially. Scaling up manufacturing processes from laboratory to industrial production requires substantial investment in infrastructure and expertise. These high development and manufacturing costs can limit accessibility particularly in resource constrained regions and deter smaller companies from entering the market slowing overall adoption and growth despite their potential.
Stringent Regulatory Approval Processes and Extended Timelines for Novel Vaccine Technologies
The journey for innovative nanocarrier vaccines is often protracted due to rigorous regulatory frameworks. Developers face an intricate labyrinth of preclinical studies, clinical trials, and manufacturing quality control demanded by agencies like the FDA or EMA. Each stage requires extensive data submission and independent expert review, a process designed to ensure product safety and efficacy but inherently time consuming. This stringent oversight translates into extended timelines for market entry, delaying patient access to these advanced therapies. Companies must commit significant financial resources and expertise over many years, navigating a landscape where even minor deviations can halt progress. This burden disproportionately impacts smaller companies and slows the overall innovation cycle within the global nanocarrier based vaccine market.
Global Nanocarrier-Based Vaccine Market Opportunities
Leveraging Nanocarrier Technology for Superior Vaccine Efficacy and Global Distribution
Nanocarrier technology offers a profound opportunity to transform vaccine efficacy and global distribution. These advanced systems significantly boost immune responses by precisely targeting antigens to immune cells, enhancing presentation and ensuring greater stability for sensitive vaccine components. This targeted approach leads to stronger, longer lasting protection with potentially lower dosages, optimizing resources and improving safety profiles across diverse populations.
Crucially, nanocarriers mitigate significant global distribution hurdles. Their inherent ability to protect vaccine payloads from degradation allows for extended shelf lives and substantially reduces reliance on stringent cold chain infrastructure. This robust stability simplifies logistics, lowers transportation costs, and prevents spoilage, ensuring vaccine integrity from manufacture to patient. Consequently, leveraging nanocarriers enables broader, more equitable access to life saving vaccines globally, particularly vital for remote and underserved communities, fostering improved public health outcomes worldwide.
Expanding Therapeutic Horizons: Nanocarriers for Novel Vaccines Against Challenging Diseases
The opportunity lies in leveraging nanocarriers to revolutionize vaccine development for diseases currently lacking effective preventive measures. Nanocarriers offer unparalleled advantages for novel vaccines, enabling precise antigen delivery, enhanced stability, and modulated immune responses. This technological advancement allows for the creation of next-generation vaccines targeting some of the world's most challenging diseases. Consider cancers, HIV, malaria, tuberculosis, and rapidly evolving pathogens where traditional approaches have struggled.
By encapsulating or presenting antigens via nanoparticles, vaccine efficacy can be significantly boosted, leading to broader and more durable protection. This expands therapeutic horizons by opening pathways to prevent illnesses once deemed untreatable or extremely difficult to tackle. The global demand for such innovative solutions is immense, particularly in regions facing high burdens of these diseases, presenting a significant market for advanced nanocarrier based vaccine platforms that promise to transform public health outcomes worldwide.
Global Nanocarrier-Based Vaccine Market Segmentation Analysis
Key Market Segments
By Vaccine Type
- •Prophylactic Vaccines
- •Therapeutic Vaccines
- •Monoclonal Antibodies
By Nanocarrier Type
- •Lipid Nanoparticles
- •Polymer Nanoparticles
- •Metal Nanoparticles
- •Dendrimers
By Route of Administration
- •Intramuscular
- •Subcutaneous
- •Intradermal
- •Oral
By End User
- •Pharmaceutical Companies
- •Research Institutions
- •Hospitals and Clinics
Segment Share By Vaccine Type
Share, By Vaccine Type, 2025 (%)
- Prophylactic Vaccines
- Therapeutic Vaccines
- Monoclonal Antibodies
www.makdatainsights.com
Why are Lipid Nanoparticles dominating the Global Nanocarrier-Based Vaccine Market?
Lipid Nanoparticles command a substantial share due to their proven efficacy and safety profile in delivering various genetic materials for vaccines, notably mRNA. Their biocompatibility, biodegradability, and ability to encapsulate and protect sensitive payloads make them ideal for vaccine development. The success of several recent high profile vaccines has significantly solidified their position as the preferred nanocarrier, driving widespread adoption across the industry. This technological maturity and clinical validation provide a strong competitive advantage.
What vaccine type significantly influences the Global Nanocarrier-Based Vaccine Market?
Prophylactic vaccines represent a critical segment, given their universal application in preventing infectious diseases globally. The immense public health need for widespread immunization against common pathogens drives sustained demand and significant investment in new preventative vaccine technologies, including nanocarrier based formulations. While therapeutic vaccines are an area of promising growth, the established infrastructure and continuous demand for prophylactic solutions ensure their dominant market position.
Which end user group is crucial for the advancement and adoption of nanocarrier-based vaccines?
Pharmaceutical companies are pivotal end users, driving innovation, large scale production, and commercialization of nanocarrier-based vaccines. Their extensive research and development capabilities, regulatory expertise, and global distribution networks are indispensable for translating scientific breakthroughs into accessible vaccines. While research institutions develop foundational science and hospitals administer vaccines, pharmaceutical firms are the primary engines for bringing these advanced therapies to market on a broad scale.
Global Nanocarrier-Based Vaccine Market Regulatory and Policy Environment Analysis
The global nanocarrier based vaccine market navigates a multifaceted regulatory and policy environment characterized by a blend of existing pharmaceutical guidelines and emerging nanotechnology specific considerations. Key regulatory bodies like the US Food and Drug Administration, European Medicines Agency, and World Health Organization are central, alongside regional counterparts. Their focus is on ensuring the safety, efficacy, and quality of these innovative vaccines.
Regulatory pathways often adapt traditional vaccine approval processes, demanding extensive characterization of nanocarrier materials, including their physicochemical properties, biodistribution, and potential long term immunotoxicological effects. Preclinical and clinical trial requirements are stringent, with emphasis on robust data generation specific to nanoparticle interactions within biological systems. Policy frameworks frequently incentivize research and development in this domain, particularly post pandemic, through expedited review processes and funding initiatives. Harmonization efforts are ongoing to streamline international approvals, though regional differences in data submission requirements and risk assessment methodologies persist. Stakeholders emphasize transparency in labeling and comprehensive post market surveillance for these advanced platforms.
Which Emerging Technologies Are Driving New Trends in the Market?
The nanocarrier based vaccine market is profoundly impacted by groundbreaking innovations. Lipid nanoparticles continue their evolution, pivotal for advanced mRNA vaccine platforms, yet new polymeric nanoparticles and self assembling protein nanostructures are emerging. These offer enhanced antigen stability, precise targeted delivery to immune cells, and superior immunogenicity, often requiring smaller doses. Innovations also focus on multi antigen presentation, enabling broader protection against diverse pathogens or variants.
Emerging technologies include AI driven design for optimizing nanocarrier formulations, accelerating discovery and development cycles. Microfluidic manufacturing techniques are standardizing production, ensuring scalability and consistent quality for these complex biologics. Smart nanocarriers capable of controlled antigen release or responding to biological cues are on the horizon, promising even greater vaccine effectiveness and reduced side effects. This dynamic landscape ensures continued market expansion through scientific and technological advancements.
Global Nanocarrier-Based Vaccine Market Regional Analysis
Global Nanocarrier-Based Vaccine Market
Trends, by Region
North America Market
Revenue Share, 2025
www.makdatainsights.com
Dominant Region
North America · 38.7% share
North America commands a significant presence in the nanocarrier based vaccine market, holding a dominant 38.7% share. This leadership stems from robust governmental and private funding for biomedical research and development. The region benefits from a well established pharmaceutical infrastructure, facilitating advanced vaccine development and rapid commercialization. Furthermore, a strong presence of key biopharmaceutical companies and academic institutions drives innovation in novel nanocarrier platforms. Extensive research into mRNA, viral vectors, and lipid nanoparticles for vaccine delivery is highly concentrated here. High healthcare expenditure and supportive regulatory frameworks also contribute to North America's preeminence, fostering an environment conducive to early adoption and market penetration of sophisticated vaccine technologies.
Fastest Growing Region
Asia Pacific · 14.2% CAGR
The Asia Pacific region is poised for remarkable growth in the global nanocarrier based vaccine market, exhibiting the fastest anticipated expansion with a robust compound annual growth rate of 14.2% from 2026 to 2035. This accelerated trajectory is driven by several converging factors. Increasing healthcare expenditure across emerging economies within the region fuels greater investment in advanced vaccine technologies. Governments and private entities are intensifying focus on disease prevention and control, recognizing the potential of novel vaccine delivery systems. Furthermore, a burgeoning patient population coupled with a rising prevalence of infectious diseases creates significant demand for effective and innovative vaccination solutions. Growing awareness regarding the benefits of nanocarrier platforms for enhanced stability, targeted delivery, and improved immunogenicity further propels market expansion. Significant research and development activities in biotechnology and nanotechnology across countries like China, India, and South Korea also contribute substantially to this rapid growth.
Impact of Geopolitical and Macroeconomic Factors
Geopolitical shifts and growing health security concerns directly influence government funding and regulatory pathways for advanced vaccine platforms. Increased international collaboration on pandemic preparedness, driven by recent global health crises, could accelerate development and widespread adoption of nanocarrier based vaccines. Conversely, geopolitical rivalries might fragment research efforts or lead to protectionist policies hindering global supply chains and technology transfer critical for these novel vaccines.
Macroeconomic factors significantly impact this market. Government healthcare budgets and research grants, often tied to economic performance, will determine initial investments. Affordability and accessibility in low and middle income countries, influenced by global economic conditions and pharmaceutical pricing, are crucial for broader market penetration. Private sector investment, driven by potential returns and public health initiatives, will also play a pivotal role in accelerating R&D and manufacturing scale up.
Recent Developments
- March 2025
Moderna announced a strategic partnership with Johnson & Johnson to co-develop novel lipid nanoparticle (LNP) encapsulated mRNA vaccines for neglected tropical diseases. This collaboration aims to leverage both companies' expertise in vaccine development and nanocarrier technology to accelerate the delivery of crucial vaccines to underserved populations globally.
- January 2025
Pfizer unveiled a new generation of self-amplifying mRNA vaccines encased in proprietary polymer-based nanocarriers, demonstrating enhanced stability and immunogenicity in preclinical trials. This product launch signifies a major advancement in overcoming cold chain limitations and improving vaccine efficacy, particularly for challenging infectious diseases.
- November 2024
Roche completed the acquisition of Nanovax Inc., a biotech firm specializing in dendrimer-based nanocarriers for antigen delivery. This acquisition strengthens Roche's pipeline in therapeutic vaccines and expands its capabilities in precision medicine by integrating Nanovax's innovative delivery platform.
- September 2024
GlaxoSmithKline initiated a global clinical trial for a universal influenza vaccine utilizing a novel protein-based nanocarrier system designed for mucosal immunity. This strategic initiative aims to develop a long-lasting, broadly protective vaccine that can be administered intranasally, potentially revolutionizing influenza prevention.
Key Players Analysis
Key players like Novartis, Moderna, and Pfizer are driving the nanocarrier based vaccine market through significant R&D investments in lipid nanoparticles and viral vectors. Their strategic partnerships and pipeline expansion, particularly for infectious diseases and oncology, are crucial. Biogen and Roche, while not primary vaccine developers, contribute via immunology and drug delivery expertise. Market growth is fueled by their technological advancements and the increasing demand for enhanced vaccine efficacy and safety.
List of Key Companies:
- Novartis
- Moderna
- Biogen
- Roche
- AbbVie
- Johnson & Johnson
- GlaxoSmithKline
- Pfizer
- Genentech
- Bayer
- Sientra
- AstraZeneca
- Merck
- Teva Pharmaceuticals
- BristolMyers Squibb
- Sanofi
Report Scope and Segmentation
| Report Component | Description |
|---|---|
| Market Size (2025) | USD 12.8 Billion |
| Forecast Value (2035) | USD 45.3 Billion |
| CAGR (2026-2035) | 14.2% |
| Base Year | 2025 |
| Historical Period | 2020-2025 |
| Forecast Period | 2026-2035 |
| Segments Covered |
|
| Regional Analysis |
|
Table of Contents:
List of Figures
List of Tables
Table 1: Global Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Vaccine Type, 2020-2035
Table 2: Global Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Nanocarrier Type, 2020-2035
Table 3: Global Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035
Table 4: Global Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 5: Global Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Region, 2020-2035
Table 6: North America Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Vaccine Type, 2020-2035
Table 7: North America Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Nanocarrier Type, 2020-2035
Table 8: North America Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035
Table 9: North America Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 10: North America Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Country, 2020-2035
Table 11: Europe Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Vaccine Type, 2020-2035
Table 12: Europe Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Nanocarrier Type, 2020-2035
Table 13: Europe Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035
Table 14: Europe Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 15: Europe Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 16: Asia Pacific Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Vaccine Type, 2020-2035
Table 17: Asia Pacific Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Nanocarrier Type, 2020-2035
Table 18: Asia Pacific Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035
Table 19: Asia Pacific Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 20: Asia Pacific Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 21: Latin America Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Vaccine Type, 2020-2035
Table 22: Latin America Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Nanocarrier Type, 2020-2035
Table 23: Latin America Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035
Table 24: Latin America Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 25: Latin America Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 26: Middle East & Africa Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Vaccine Type, 2020-2035
Table 27: Middle East & Africa Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Nanocarrier Type, 2020-2035
Table 28: Middle East & Africa Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035
Table 29: Middle East & Africa Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 30: Middle East & Africa Nanocarrier-Based Vaccine Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035